Effects of latanoprost, timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist on LTC4 release after rat mast cell activation
Article first published online: 3 SEP 2007
Clinical & Experimental Ophthalmology
Volume 35, Issue 7, pages 645–650, September/October 2007
How to Cite
Laengle, U. W., Markstein, R., Pralet, D., Seewald, W. and Roman, D. (2007), Effects of latanoprost, timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist on LTC4 release after rat mast cell activation. Clinical & Experimental Ophthalmology, 35: 645–650. doi: 10.1111/j.1442-9071.2007.01560.x
- Issue published online: 24 SEP 2007
- Article first published online: 3 SEP 2007
- Received 21 November 2006; accepted 20 June 2007.
- dopamine D1 receptor antagonist;
- dopamine D2 receptor agonist;
- in vitro model;
- mast cells;
- topical glaucoma medication
Purpose: Mast cells participate in ocular allergic inflammation by releasing biologically active mediators. Leukotrienes are released from activated mast cells via an IgE-dependent mechanism, and play a crucial role in ocular allergic inflammation. In this study, the effect of three topical antiglaucoma drugs, that is, latanoprost, timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist, on leukotriene C4 (LTC4) release after rat mast cell activation was examined.
Methods: A rat basophilic leukaemia RBL-2H3 mast cell line was activated via IgE/anti-IgE. Rat mast cells were incubated with latanoprost, timolol, or GLC756 at concentrations of 0.1, 1, 10 and 30 μM. LTC4 concentration in supernatant was assessed 5 h post activation by EIA.
Results: Compared with controls, timolol showed no relevant effect on LTC4 release, 5 h after mast cell activation. Latanoprost and GLC756, in contrast, revealed an inhibitory effect on LTC4 release, which was dose-related and statistically significant at the concentrations of 10 and 30 μM.
Conclusion: The results of this study suggest that timolol has no significant influence on LTC4 release from activated mast cells. By contrast, latanoprost and GLC756 inhibited LTC4 release, suggesting a possible anti-inflammatory effect on ocular allergic inflammatory processes in topical glaucoma medication.